Cover Image

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract

As a result of the high approval dynamics and the growing number of immuno-oncological concepts, the complexity of treatment decisions and control in the area of cancers of the esophagus, gastroesophageal junction and stomach is constantly increasing. Since the treatment indication for PD-1 inhibito...

Full description

Saved in:
Bibliographic Details
Main Authors: Baretton, Gustavo Bruno (Author) , Lordick, Florian (Author) , Gaiser, Timo (Author) , Hofheinz, Ralf-Dieter (Author) , Horst, David (Author) , Lorenzen, Sylvie (Author) , Möhler, Markus (Author) , Röcken, Christoph (Author) , Schirmacher, Peter (Author) , Stahl, Michael (Author) , Thuss-Patience, Peter (Author) , Tiemann, Klaus (Author)
Format: Article (Journal)
Language:English
Published: 24 October 2023
In: Journal of cancer research and clinical oncology
Year: 2023, Volume: 149, Pages: 16231-16238
ISSN:1432-1335
DOI:10.1007/s00432-023-05180-5
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00432-023-05180-5
Get full text
Author Notes:Gustavo B. Baretton, Florian Lordick, The Interdisciplinary Expert Group, T. Gaiser, R. Hofheinz, D. Horst, S. Lorenzen, M. Moehler, C. Röcken, P. Schirmacher, M. Stahl, P. Thuss-Patience, K. Tiemann
Description
Summary:As a result of the high approval dynamics and the growing number of immuno-oncological concepts, the complexity of treatment decisions and control in the area of cancers of the esophagus, gastroesophageal junction and stomach is constantly increasing. Since the treatment indication for PD-1 inhibitors that are currently approved in the European Union is often linked to the expression of PD-L1 (programmed cell death-ligand 1), the evaluation of tissue-based predictive markers by the pathologist is of crucial importance for treatment stratification. Even though the immunohistochemical analysis of the PD-L1 expression status is one of the best studied, therapy-relevant biomarkers for an immuno-oncological treatment, due to the high heterogeneity of carcinomas of the upper gastrointestinal tract, there are challenges in daily clinical diagnostic work with regard to implementation, standardization and interpretation of testing. An interdisciplinary group of experts from Germany has taken a position on relevant questions from daily pathological and clinical practice, which concern the starting material, quality-assured testing and the interpretation of pathological findings, and has developed recommendations for structured reporting.
Item Description:Gesehen am 13.12.2023
Physical Description:Online Resource
ISSN:1432-1335
DOI:10.1007/s00432-023-05180-5

Similar Items